Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.44 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.44 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14384753 | 0.88 | SLC6A1 (0.60) | EPHX1GABRA5GABRB2SLC6A1SLC6A12 | |
| SCHEMBL14097636 | 0.88 | SLC6A1 (0.60) | EPHX1GABRA5GABRB2SLC6A1SLC6A12 | |
| SCHEMBL14097417 | 0.88 | SLC6A1 (0.60) | EPHX1GABRA5GABRB2SLC6A1SLC6A12 | |
| SCHEMBL104261 | 0.84 | — | — | |
| SCHEMBL1802276 | 0.81 | EPHX1 (0.54) | EPHX1GABRA5GABRB2SLC6A1SLC6A12 | |
| SCHEMBL3654074 | 0.80 | KMT2A (0.57) | EPHX1HPGDKMT2AEPHX2 | |
| SCHEMBL8393335 | 0.80 | — | — | |
| SCHEMBL5645399 | 0.80 | EPHX1 (0.50) | EPHX1GABRA5GABRB2SLC6A1SLC6A12 | |
| SCHEMBL6230136 | 0.80 | TNKS2 (0.45) | EPHX1ALOX15GNAI3GNAO1GNAI1 | |
| SCHEMBL29341681 | 0.79 | SIGMAR1 (0.41) | EPHX1GNAO1ANPEPERAP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3724178-B1 | 1-(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024073576-A1 | 4-((2-(3,5-DICHLOROPHENYL)-6-((PYRIMIDIN-5-YL)OXY)PYRIDIN-4-YL)METHYL)PIPERAZINE DERIVATIVES AS FURIN INHIBITORS AND USES THEREOF | BP ASSET V, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4313991-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2016021562-A1 | CYANOTHIOPHENE DERIVATIVE | キッセイ薬品工業株式会社 | 2016-02-11 | — | — | WO | disclosed |
| WO-2013178591-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
| EP-1045693-A1 | AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS | SUNTORY LIMITED (JP) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000023076-A1 | AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS | SUNTORY LIMITED (JP) | 2000-04-27 | — | — | WO | disclosed |
| US-4289772-A | PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | EPHX1 2439/4885GABRA5 3619/4885GABRB2 2330/4885 |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | EPHX1 2606/4885GABRA5 4199/4885GABRB2 2531/4885 |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | EPHX1 1649/4885GABRA5 170/4885GABRB2 1213/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | EPHX1 3269/4885GABRA5 1888/4885GABRB2 1512/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | EPHX1 4072/4885GABRA5 2241/4885GABRB2 1490/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | EPHX1 2385/4885GABRA5 3243/4885GABRB2 1360/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | EPHX1 1149/4885GABRA5 1519/4885GABRB2 880/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | EPHX1 1649/4885GABRA5 170/4885GABRB2 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.